MX2022006086A - Derivados de piridopirimidinona como antagonistas de ahr. - Google Patents

Derivados de piridopirimidinona como antagonistas de ahr.

Info

Publication number
MX2022006086A
MX2022006086A MX2022006086A MX2022006086A MX2022006086A MX 2022006086 A MX2022006086 A MX 2022006086A MX 2022006086 A MX2022006086 A MX 2022006086A MX 2022006086 A MX2022006086 A MX 2022006086A MX 2022006086 A MX2022006086 A MX 2022006086A
Authority
MX
Mexico
Prior art keywords
same
compounds
preparing
methods
useful
Prior art date
Application number
MX2022006086A
Other languages
English (en)
Inventor
Steven John Taylor
Leonard Buckbinder
Bernard Lanter
Timothy Briggs
Alessandra Bartolozzi
John Robert Proudfoot
John Mancuso
Karunakar Reddy Bonepally
Patrick Bureau
Tianlin Guo
Maxence Bos
Anna Blois
Francesca Barone
Original Assignee
Senda Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senda Biosciences Inc filed Critical Senda Biosciences Inc
Publication of MX2022006086A publication Critical patent/MX2022006086A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación se refiere a compuestos de Fórmula (la) y sales farmacéuticamente aceptables de los mismos, a composiciones farmacéuticas que comprenden los mismos, a métodos para preparar los mismos, a compuestos intermedios útiles para preparar los mismos y a métodos para el tratamiento o la profilaxis de enfermedades, en particular cáncer o afecciones con respuestas inmunitarias desreguladas u otros trastornos asociados con una señalización aberrante de AHR. Estos compuestos también pueden ser útiles en el tratamiento del cáncer cuando se administran en combinación con al menos una terapia adicional. (ver fórmula).
MX2022006086A 2019-11-22 2020-11-20 Derivados de piridopirimidinona como antagonistas de ahr. MX2022006086A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962939377P 2019-11-22 2019-11-22
US202063050416P 2020-07-10 2020-07-10
US202063091192P 2020-10-13 2020-10-13
PCT/US2020/061548 WO2021102288A1 (en) 2019-11-22 2020-11-20 Pyridopyrimidinone derivatives as ahr antagonists

Publications (1)

Publication Number Publication Date
MX2022006086A true MX2022006086A (es) 2022-09-07

Family

ID=73854915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006086A MX2022006086A (es) 2019-11-22 2020-11-20 Derivados de piridopirimidinona como antagonistas de ahr.

Country Status (13)

Country Link
US (1) US20230295152A1 (es)
EP (1) EP4061484A1 (es)
JP (1) JP2023502476A (es)
KR (1) KR20220119537A (es)
CN (1) CN115397512A (es)
AU (1) AU2020386967A1 (es)
BR (1) BR112022009805A2 (es)
CA (1) CA3162236A1 (es)
CL (1) CL2022001337A1 (es)
CO (1) CO2022008606A2 (es)
IL (1) IL293103A (es)
MX (1) MX2022006086A (es)
WO (1) WO2021102288A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115443276A (zh) * 2020-04-17 2022-12-06 东亚St株式会社 吡啶并嘧啶酮衍生物及其作为芳烃受体调节剂的应用
US20230381182A1 (en) 2020-10-13 2023-11-30 Senda Biosciences, Inc. Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same
CN114644627B (zh) * 2020-12-18 2024-06-11 山东轩竹医药科技有限公司 AhR抑制剂及其用途
WO2022217042A1 (en) * 2021-04-09 2022-10-13 Ikena Oncology, Inc. Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
CN115093400B (zh) * 2021-09-18 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂及其用途和制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2846657B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP7232244B2 (ja) * 2017-04-21 2023-03-08 イケナ オンコロジー， インコーポレイテッド インドールａｈｒ阻害剤およびその使用
US10815250B2 (en) * 2018-02-06 2020-10-27 Ideaya Biosciences, Inc. AhR modulators
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
CN115443276A (zh) * 2020-04-17 2022-12-06 东亚St株式会社 吡啶并嘧啶酮衍生物及其作为芳烃受体调节剂的应用

Also Published As

Publication number Publication date
CA3162236A1 (en) 2021-05-27
CL2022001337A1 (es) 2023-05-05
KR20220119537A (ko) 2022-08-29
US20230295152A1 (en) 2023-09-21
IL293103A (en) 2022-07-01
WO2021102288A1 (en) 2021-05-27
EP4061484A1 (en) 2022-09-28
CN115397512A (zh) 2022-11-25
JP2023502476A (ja) 2023-01-24
CO2022008606A2 (es) 2022-09-20
AU2020386967A1 (en) 2022-07-07
BR112022009805A2 (pt) 2022-08-16

Similar Documents

Publication Publication Date Title
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
TN2016000458A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer.
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
GB201104267D0 (en) Pyrrolopyridineamino derivatives
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
PH12020551494A1 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
MX2022001952A (es) Compuestos de alquinil quinazolina.
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2018008272A (es) Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12017501736A1 (en) Indole derivatives